Clinical

Glioblastoma multiforme is the most common malignant primary brain tumor in adults and is associated with poor survival rates. Symptoms often include headaches; nausea and vomiting; and progressive memory, personality, or neurologic deficits. The treatment remains a challenge, and despite the approval of multiple new therapies in the past decade, survival has not improved.
Treatment Decisions in the Management of Malignant Gliomas
The diagnosis of prostate cancer is dependent on histologic confirmation in biopsy core tissues. The biopsy procedure is invasive, puts the patient at risk for complications, and is subject to significant sampling errors.
Molecular Tests Can Help to Reduce Repeated Prostate Biopsies
The diagnosis of prostate cancer is dependent on histologic confirmation in biopsy core tissues. The biopsy procedure is invasive, puts the patient at risk for complications, and is subject to significant sampling errors.
Molecular Tests Can Help to Reduce Repeated Prostate Biopsies
Crohn’s disease is a chronic relapsing form of inflammatory bowel disease and is characterized by inflammation of the gastrointestinal tract. It is estimated that 1.4 million persons in the United States and 2.2 million persons in Europe have inflammatory bowel disease. The most recent and advanced approach to the treatment of Crohn’s disease is biologic therapy designed to neutralize the proinflammatory effects of the cytokine tumor necrosis factor (TNF)-alpha.
Infliximab Dosing for Crohn’s Disease: Too Much of a Good Thing?
The use of anti–tumor necrosis factor (TNF) medications for the treatment of chronic inflammatory conditions, such as rheumatoid arthritis (RA), Crohn’s disease, or psoriasis, represents a large and growing healthcare expenditure. For example, a 2013 sales forecast for adalimumab, the most frequently used injectable anti-TNF, projected continued growth in annual sales from $9.2 billion to $11.2 billion in 2016, and infliximab, an intravenous (IV) infusion anti-TNF, generated more than $7 billion in revenue in 2012.
In a Fix on Addressing Alternatives

Acne vulgaris is a chronic skin disease predominantly affecting the face, trunk, and back.1 The prevalence of acne vulgaris is high in many countries: acne afflicts up to 87% of adolescents and up to 54% of adults.2,3 Skin diseases, including acne, are often dismissed as being trivial or not as important as diseases of other organ systems.4 However, acne can negatively affect the patient’s quality of life (QOL).4 Responses to the 36-Item Short Form Survey, a generic QOL questionnaire, demonstrate that patients with acne report social, psychological, and emotional problems at levels as great as patients with epilepsy, diabetes, back pain, disabling asthma, or arthritis.4 Patients with acne also have fewer feelings of pride, lower self-esteem, lower body image satisfaction, more depressive symptoms, and more feelings of uselessness than people without acne.5 Adolescents with severe acne have suicidal thoughts more frequently than those with less severe acne.6 If left untreated, acne can result in significant psychosocial morbidity.7 Treatment improves the QOL of patients with acne and can prevent scarring.8-10

Evaluating Treatments for Acne: It’s Time to “Sweat” the Smaller Things
Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of chemotherapy, and may present during or soon after (0-24 hours) chemotherapy administration (ie, acute CINV) or between 25 to 120 hours after chemotherapy administration (ie, delayed CINV).1,2 In the absence of antiemetic prophylaxis, many emetogenic agents will cause emesis in more than 90% of patients within 24 hours of the administration of chemotherapy.1-3 Preventing CINV during the initiation of chemotherapy is important, because the risk for CINV in future chemotherapy cycles increases if CINV occurs in the first or previous treatment cycle.4-8 The 5-hydroxytryptamine3 receptor antagonists (5-HT3-RAs) have proved to be very effective in the prevention of CINV, with current guidelines supporting the use of the 5-HT3-RA agents for CINV prophylaxis.9-11
Value of Selecting the Best Antiemetic Prophylactic Agent for Patients Using Chemotherapy
Diabetic retinopathy is a retinal vascular disorder that affects more than 4.1 million people in the United States. New methods of detecting and ensuring adequate follow-up of this life-altering disease are vital to improving patient outcomes. Wills Eye Hospital and the Centers for Disease Control and Prevention are conducting a collaborative study to initiate a novel diabetic retinopathy screening in the community setting.
Screening for Diabetic Retinopathy in the Community Setting: Exploring the Options
Obesity is a serious and costly disease that is growing in epidemic proportions. Obesity-related hospitalizations have nearly tripled from 1996 to 2009. If the current trend in the growth of obesity continues, the total healthcare costs attributable to obesity could reach $861 billion to $957 billion by 2030. The American Medical Association has officially recognized obesity as a disease. Obesity is a public health crisis affecting approximately more than 33% of Americans and costing the healthcare system more than $190 billion annually.
The Modern Epidemic of Obesity

According to the American Cancer Society, more than 1.6 million people will receive a new diagnosis of cancer in 2013.1 It is also estimated that there were almost 14 million cancer survivors (ie, any living person who has ever received a diagnosis of cancer) in the United States in 2012.2 Although many aggressive forms of cancer still exist, individuals who receive a diagnosis of cancer today are less likely to die from their disease than in the past; the death rate from cancer has decreased by 20% since 1991.1 However, the number of cancer diagnoses is inc

Quality of Cancer Care: Emerging Definition and Measurements, but Reimbursement Lagging
Page 7 of 13
Results 61 - 70 of 122
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME